Barclays Downgrades Bristol-Myers Squibb to Underweight, Maintains Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has downgraded Bristol-Myers Squibb (NYSE:BMY) from Equal-Weight to Underweight while maintaining the price target at $41.
July 29, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays analyst Carter Gould has downgraded Bristol-Myers Squibb from Equal-Weight to Underweight, maintaining the price target at $41. This downgrade could lead to a negative short-term impact on BMY's stock price.
The downgrade from Equal-Weight to Underweight by a major analyst like Barclays typically signals a negative outlook on the stock, which can lead to selling pressure and a decline in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100